Skip to main content
Midas Edge

Enveric Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

ENVB$1.44+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ENVERIC BIOSCIENCES, INC.
March 27, 2026By:/s/ Joseph Tucker
Joseph Tucker, Ph.D.
Chief Executive Officer
(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

March 27, 2026By:/s/ Joseph Tucker
Joseph Tucker, Ph.D.
Chief Executive Officer
(Principal Executive Officer)
March 27, 2026By:/s/ Kevin Coveney
Kevin Coveney
Chief Financial Officer
(Principal Financial and Accounting Officer)
March 27, 2026By:/s/ Michael Webb
Michael Webb
Director
March 27, 2026By:/s/ George Kegler
George Kegler
Director
March 27, 2026By:/s/ Marcus Schabacker
Marcus Schabacker, Ph.D., M.D.
Director
March 27, 2026By:/s/ Frank Pasqualone
Frank Pasqualone
Director
March 27, 2026By:/s/ Sheila DeWitt
Sheila DeWitt, Ph.D.
Director
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.